Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.46 |
| ▸ | MET | P08581 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989799 | 0.86 | SIRT6 (0.41) | SIRT6METMAPTLMNAALDH1A1 | |
| SCHEMBL27678434 | 0.82 | MET (0.43) | SIRT6METMAPTLMNAPOLB | |
| SCHEMBL24073869 | 0.77 | SIRT6 (0.60) | SIRT6METMAPTLMNAALDH1A1 | |
| SCHEMBL990747 | 0.75 | MAPT (0.45) | MAPTLMNAPOLBALDH1A1L3MBTL1 | |
| SCHEMBL26655887 | 0.72 | ALDH1A1 (0.55) | LMNAPOLBALDH1A1 | |
| SCHEMBL6522223 | 0.70 | HTR3A (0.53) | METMAPTLMNAALDH1A1HTR6 | |
| SCHEMBL4081314 | 0.70 | RAB9A (0.41) | SIRT6MAPTLMNAALDH1A1MAPK1 | |
| SCHEMBL13405746 | 0.68 | ALDH1A1 (0.48) | SIRT6METMAPTLMNAALDH1A1 | |
| SCHEMBL3550715 | 0.68 | SIRT6 (0.57) | SIRT6MAPTLMNAPOLBALDH1A1 | |
| SCHEMBL2256754 | 0.67 | SIRT6 (0.52) | SIRT6METMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | SIRT6 1801/4885MET 2767/4885MAPT 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.